Sign In
Buy MNMD
$20.69
+0 (+0%)
At Close: Jun 18, 2026
Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript
09:48pm, Thursday, 31'st Jul 2025
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Brandi L. Roberts - Chief Financial Officer Daniel Rollings Karlin - Chief Me
MindMed Reports Q2 2025 Financial Results and Business Updates
04:01pm, Thursday, 31'st Jul 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025
07:00am, Thursday, 24'th Jul 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy
01:01pm, Tuesday, 22'nd Jul 2025
Mind Medicine MindMed (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MindMed Announces New Employee Inducement Grants
04:01pm, Monday, 14'th Jul 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
MindMed Announces New Employee Inducement Grants
04:01pm, Monday, 09'th Jun 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
Why Mind Medicine Gave Investors a Powerful Buzz in May
07:02am, Wednesday, 04'th Jun 2025
Mind Medicine (MNMD 2.81%), a healthcare company that's looking to develop treatments based on psychedelic compounds, was something of a sleeper stock in May. Several positive developments pushed the
Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade
11:01am, Monday, 02'nd Jun 2025
The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 237.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
MindMed to Participate in June Investor Conferences
07:00am, Wednesday, 28'th May 2025
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidat
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer
07:00am, Tuesday, 27'th May 2025
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to t
Why Mind Medicine Stock Vaulted More Than 8% Higher Today
05:33pm, Tuesday, 20'th May 2025
Investors had a good mind to plow money into Mind Medicine (MNMD 8.13%) stock on Tuesday. Shares of the psychedelic-focused biotech, which also goes by the name of MindMed, provided a nice high by ris
MindMed Announces New Employee Inducement Grants
04:01pm, Monday, 19'th May 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?
11:01am, Tuesday, 13'th May 2025
The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 279.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript
09:55am, Thursday, 08'th May 2025
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - Chief Executive
MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates
07:00am, Thursday, 08'th May 2025
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to t
